Professional Summary
Professional Overview
Annette Marcantonio is a seasoned pharmaceutical and biotechnology executive with over 30 years of experience in clinical operations and drug development. She currently serves as the Vice President of Clinical Operations at Jasper Therapeutics and Pacylex Pharmaceuticals, where she is responsible for leading the strategic planning and execution of complex clinical trials. Annette's expertise spans the full lifecycle of drug development, from early-stage clinical trials to late-stage commercialization.
Experience Summary
Current Role
As Vice President of Clinical Operations at Jasper Therapeutics, Annette is responsible for overseeing the successful implementation of the company's clinical development programs. She works closely with cross-functional teams to ensure efficient study design, timely patient enrollment, and effective data management. Under her leadership, Jasper Therapeutics has been able to advance multiple investigational therapies through the clinical pipeline.
In her concurrent role as Vice President of Clinical Operations at Pacylex Pharmaceuticals, Annette leads the strategic planning and operational execution of the company's clinical trials. She has a proven track record of driving innovative study designs and collaborating with regulatory agencies to expedite the development of Pacylex's pipeline of oncology and rare disease therapies.
Career Progression
Prior to her current roles, Annette held various senior-level positions in the pharmaceutical and biotechnology industry, including Vice President of Clinical Affairs at Neurogastrx, Vice President of Clinical Operations at Aimmune Therapeutics, and Senior Director of Clinical Operations at Alvine Pharmaceuticals and Nektar Therapeutics. Throughout her career, she has leveraged her deep understanding of the regulatory landscape and her expertise in patient recruitment and site management to deliver successful clinical programs.
Annette has also maintained an active presence as a clinical development consultant, providing strategic guidance to companies such as Genentech, Xenoport, and Oculex (now Allergan). Her consultancy work has enabled her to stay abreast of emerging industry trends and best practices, which she has seamlessly integrated into her leadership roles.
Academic Background
Annette holds a Bachelor of Science degree from the University of California, Los Angeles, where she specialized in Biological Sciences. Her academic achievements and strong scientific foundation have been instrumental in her ability to navigate the complexities of the pharmaceutical and biotechnology industries.
Areas of Expertise
- Clinical trial design, implementation, and management
- Regulatory affairs and interaction with global health authorities
- Patient recruitment and site management strategies
- Cross-functional collaboration and team leadership
- Strategic planning and execution of drug development programs
- Consultative expertise in the biotechnology and pharmaceutical sectors
Professional Impact
Throughout her career, Annette has demonstrated a proven track record of successfully advancing investigational therapies through the clinical pipeline. Her contributions have been instrumental in the development of multiple FDA-approved products, positively impacting the lives of patients worldwide.
Annette's industry expertise and thought leadership have been recognized by her peers, and she has been invited to speak at numerous industry conferences and events. She is known for her ability to navigate complex regulatory landscapes, foster effective collaborations, and drive operational excellence in clinical development.
Conclusion
With her extensive experience, proven leadership skills, and deep technical expertise, Annette Marcantonio is a highly sought-after executive in the pharmaceutical and biotechnology industries. Her demonstrated ability to navigate the complexities of drug development and deliver successful clinical programs positions her as a valuable asset to any organization seeking to accelerate the advancement of life-changing therapies.
